BRIEF—Broader NICE reimbursement for Janssen's Tremfya

The National Institute for Health and Care Excellence (NICE) has updated its recommendation for Tremfya (guselkumab), alone or with methotrexate, as an option for treating active psoriatic arthritis (PsA) in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs or who cannot tolerate them.

With this latest recommendation, the National Health Service (NHS) will now make the Janssen drug available in England and Wales to a wider group of patients with PsA, without restrictions based on psoriasis (PsO) symptom severity.

Amanda Cunnington, patient access director, Janssen-Cilag, said: “We are pleased to welcome the latest recommendation from NICE which means guselkumab will be available for an expanded group of eligible PsA patients with fewer restrictions, in addition to those eligible patients with PsO. It is a vital step towards improving outcomes for people living with PsA, PsO, or both these debilitating conditions.

“We look forward to working with NICE and the NHS to ensure that treatments, like guselkumab, are available for use in clinical practice as quickly as possible as an alternative treatment for eligible patients.”